What Castle Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 74 | 216 |
| Total trades | 85 | 286 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 87,208 | 590,912 |
| Disposed | 265,876 | 755,381 |
| Net activity | −178,668 | −164,469 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Maetzold Derek J | Pres. & Chief Exec. Officer | Oct 19 | Open-market sale · S | −2,718 | $31.91 | −$86.7K | 4,114 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Oct 19 | Open-market sale · S | −3,198 | $31.91 | −$102K | 4,840 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Oct 19 | Open-market sale · S | −8,580 | $31.91 | −$274K | 12,484 |
| Juvenal Tobin W | Chief Commercial Officer | Oct 12 | Open-market sale · S | −3,288 | $33.64 | −$111K | 48,719 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Oct 05 | Open-market sale · S | −2,718 | $35.57 | −$96.7K | 6,832 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Oct 05 | Open-market sale · S | −3,198 | $35.57 | −$114K | 8,038 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Oct 05 | Open-market sale · S | −8,580 | $35.57 | −$305K | 21,064 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Oct 05 | Exercise / conversion · M | +8,165 | $2.39 | +$19.5K | 29,644 |
| Oelschlager Kristen M | Chief Operating Officer | Oct 01 | Open-market sale · S | −1,346 | $36.38 | −$49K | 13,356 |
| Oelschlager Kristen M | Chief Operating Officer | Oct 01 | Open-market sale · S | −2,807 | $35.75 | −$100K | 14,702 |
| Oelschlager Kristen M | Chief Operating Officer | Oct 01 | Exercise / conversion · M | +4,153 | $3.38 | +$14K | 17,509 |
| Juvenal Tobin W | Chief Commercial Officer | Sep 30 | Open-market sale · S | −1,034 | $34.20 | −$35.4K | 52,007 |
| Juvenal Tobin W | Chief Commercial Officer | Sep 29 | Open-market sale · S | −5,543 | $35.50 | −$197K | 53,041 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Sep 21 | Open-market sale · S | −2,718 | $35.33 | −$96K | 9,550 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Sep 21 | Open-market sale · S | −3,198 | $35.33 | −$113K | 11,236 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Sep 21 | Open-market sale · S | −8,580 | $35.33 | −$303K | 21,479 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Sep 21 | Exercise / conversion · M | +8,580 | $2.39 | +$20.5K | 30,059 |
| Juvenal Tobin W | Chief Commercial Officer | Sep 15 | Open-market sale · S | −3,294 | $35.14 | −$116K | 58,584 |
| Juvenal Tobin W | Chief Commercial Officer | Sep 14 | Open-market sale · S | −3,306 | $32.32 | −$107K | 61,878 |
| Maetzold Derek J | Pres. & Chief Exec. Officer | Sep 11 | Open-market sale · S | −71 | $32.78 | −$2.33K | 12,268 |
Loading...